115 related articles for article (PubMed ID: 24337418)
1. Characterisation of the p.A1461D mutation causing von Willebrand disease type 2B with severe thrombocytopenia, circulating giant platelets, and defective α-granule secretion.
Langer F; Obser T; Oyen F; Spath B; Holstein K; Greinacher A; White JG; Budde U; Bokemeyer C; Schneppenheim R
Thromb Haemost; 2014 Apr; 111(4):777-9. PubMed ID: 24337418
[No Abstract] [Full Text] [Related]
2. Genotyping might help therapeutic decision-making in patients with von Willebrand disease type 2 B.
Rugeri L; Fretigny M; Dargaud Y; Nougier C; Vinciguerra C
Haemophilia; 2016 Sep; 22(5):e439-43. PubMed ID: 27353798
[No Abstract] [Full Text] [Related]
3. Type 2B von Willebrand Disease: A Matter of Plasma Plus Platelet Abnormality.
Castaman G; Federici AB
Semin Thromb Hemost; 2016 Jul; 42(5):478-82. PubMed ID: 27148840
[TBL] [Abstract][Full Text] [Related]
4. An update on type 2B von Willebrand disease.
Mikhail S; Aldin ES; Streiff M; Zeidan A
Expert Rev Hematol; 2014 Apr; 7(2):217-31. PubMed ID: 24521271
[TBL] [Abstract][Full Text] [Related]
5. Thrombin generation in the presence of platelets is sensitive to the activation status of von Willebrand factor.
Pelkmans L; Miszta A; Al Dieri R; de Laat B; Kelchtermans H
Thromb Haemost; 2015 Jan; 113(1):209-11. PubMed ID: 25274249
[No Abstract] [Full Text] [Related]
6. Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets.
Casari C; Paul DS; Susen S; Lavenu-Bombled C; Harroche A; Piatt R; Poe KO; Lee RH; Bryckaert M; Christophe OD; Lenting PJ; Denis CV; Bergmeier W
Blood Adv; 2018 Jun; 2(12):1417-1428. PubMed ID: 29925524
[TBL] [Abstract][Full Text] [Related]
7. Platelet abnormalities in a family with von Willebrand disease type 2B (V1316M) and association with bleeding score.
Guglielmone HA; Smith N; Minoldo S; Jarchum GD; White-Adams T; Di Paola J
Haemophilia; 2016 Sep; 22(5):e455-8. PubMed ID: 27385556
[No Abstract] [Full Text] [Related]
8. How I treat type 2B von Willebrand disease.
Kruse-Jarres R; Johnsen JM
Blood; 2018 Mar; 131(12):1292-1300. PubMed ID: 29378695
[TBL] [Abstract][Full Text] [Related]
9. Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation.
Casonato A; Steffan A; Pontara E; Zucchetto A; Rossi C; De Marco L; Girolami A
Thromb Haemost; 1999 Feb; 81(2):224-8. PubMed ID: 10063996
[TBL] [Abstract][Full Text] [Related]
10. Prospective study of low-dose ristocetin-induced platelet aggregation to identify type 2B von Willebrand disease (VWD) and platelet-type VWD in children.
Frontroth JP; Hepner M; Sciuccati G; Feliú Torres A; Pieroni G; Bonduel M
Thromb Haemost; 2010 Dec; 104(6):1158-65. PubMed ID: 20941465
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of thrombocytopenia in platelet-type von Willebrand disease.
Bury L; Malara A; Momi S; Petito E; Balduini A; Gresele P
Haematologica; 2019 Jul; 104(7):1473-1481. PubMed ID: 30655369
[TBL] [Abstract][Full Text] [Related]
12. A second report of platelet-type von Willebrand disease with a Gly233Ser mutation in the GPIBA gene.
Nurden P; Lanza F; Bonnafous-Faurie C; Nurden A
Thromb Haemost; 2007 Feb; 97(2):319-21. PubMed ID: 17264965
[No Abstract] [Full Text] [Related]
13. A family having type 2B von Willebrand disease with an R1306W mutation: Severe thrombocytopenia leads to the normalization of high molecular weight multimers.
Ozeki M; Kunishima S; Kasahara K; Funato M; Teramoto T; Kaneko H; Fukao T; Kondo N
Thromb Res; 2010 Feb; 125(2):e17-22. PubMed ID: 19740526
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of platelet functional alterations in patients with filamin A mutations.
Berrou E; Adam F; Lebret M; Fergelot P; Kauskot A; Coupry I; Jandrot-Perrus M; Nurden A; Favier R; Rosa JP; Goizet C; Nurden P; Bryckaert M
Arterioscler Thromb Vasc Biol; 2013 Jan; 33(1):e11-8. PubMed ID: 23117662
[TBL] [Abstract][Full Text] [Related]
15. Differential diagnosis between type 2A and 2B von Willebrand disease in a child with a previously undescribed de novo mutation.
Pagliari MT; Baronciani L; Stufano F; Colpani P; Siboni SM; Peyvandi F
Haemophilia; 2018 Jul; 24(4):e263-e266. PubMed ID: 30044032
[No Abstract] [Full Text] [Related]
16. Acquired von Willebrand syndrome type 2A in a JAK2-positive essential thrombocythaemia-affected member of a large von Willebrand disease family with a novel autosomal dominant A1716P mutation.
Giannini S; Solimando M; Fierro T; Baronciani L; Federici AB; Gresele P
Thromb Haemost; 2011 May; 105(5):921-4. PubMed ID: 21359411
[No Abstract] [Full Text] [Related]
17. Biomedicine. Contact--how platelets touch von Willebrand factor.
Sadler JE
Science; 2002 Aug; 297(5584):1128-9. PubMed ID: 12183613
[No Abstract] [Full Text] [Related]
18. Identification of a novel 14-3-3zeta binding site within the cytoplasmic domain of platelet glycoprotein Ibalpha that plays a key role in regulating the von Willebrand factor binding function of glycoprotein Ib-IX.
Yuan Y; Zhang W; Yan R; Liao Y; Zhao L; Ruan C; Du X; Dai K
Circ Res; 2009 Dec; 105(12):1177-85. PubMed ID: 19875727
[TBL] [Abstract][Full Text] [Related]
19. Platelet activation and aggregation induced by recombinant von Willebrand factors reproducing four type 2B von Willebrand disease missense mutations.
de Romeuf C; Hilbert L; Mazurier C
Thromb Haemost; 1998 Jan; 79(1):211-6. PubMed ID: 9459349
[TBL] [Abstract][Full Text] [Related]
20. Measurement of von Willebrand factor binding to a recombinant fragment of glycoprotein Ibalpha in an enzyme-linked immunosorbent assay-based method: performances in patients with type 2B von Willebrand disease.
Caron C; Hilbert L; Vanhoorelbeke K; Deckmyn H; Goudemand J; Mazurier C
Br J Haematol; 2006 Jun; 133(6):655-63. PubMed ID: 16704443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
